共 50 条
- [21] Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patientsONKOLOGIE, 2003, 26 (02): : 115 - 119Ploner, FJakesz, RHausmaninger, HKolb, RStierer, MFridrikf, MSteindorfer, PGnant, MHaider, KMlineritsch, BTschurtschenthaler, GSteger, GSeifert, MKubista, ESamonigg, H
- [22] Effectiveness of neoadjuvant anthracycline-containing chemotherapy schemes with/without taxane compared with CMF in women with early breast cancerGEBURTSHILFE UND FRAUENHEILKUNDE, 2007, 67 (05) : 524 - 524Gschwantler-Kaulich, D.Fink-Retter, A.Bachrich, T.Ruecklinger, E.Kubista, E.Singer, C. F.
- [23] Tumor-infiltrating lymphocytes to predict survival to anthracycline/taxane-based neoadjuvant chemotherapy in breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)Ou, QiyunYu, YunfangXiao, XiaoyunLuo, Baoming
- [24] Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancerKOREAN JOURNAL OF INTERNAL MEDICINE, 2021, 36 (01): : 182 - +Joung, Eun KyoYang, Ji HyunOh, SooeunPark, Se JunLee, Jieun
- [25] The prognostic significance of Ki-67 expression before and after neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypesCANCER RESEARCH, 2013, 73Zhang, J.Zhang, X.Yu, F.Liu, J.Zhang, S.Hao, X.Hou, G.
- [26] Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimensMedical Oncology, 2012, 29 : 547 - 553Shusen WangYanxia ShiZhongyu YuanXi WangDonggen LiuRoujun PengXiaoyu TengTao QinJiewen PengGuinan LinXiaomei Jiang
- [27] Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimensMEDICAL ONCOLOGY, 2012, 29 (02) : 547 - 553Wang, ShusenShi, YanxiaYuan, ZhongyuWang, XiLiu, DonggenPeng, RoujunTeng, XiaoyuQin, TaoPeng, JiewenLin, GuinanJiang, Xiaomei
- [28] PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapyCANCER RESEARCH, 2012, 72Liu, M. C.Pitcher, B. N.Mardis, E. R.Davies, S. R.Snider, J. E.Vickery, T.Reed, J. P.DeSchryver, K.Singh, B.Friedman, P. N.Gradishar, W. J.Perez, E. A.Martino, S.Citron, M. L.Norton, L.Winer, E. P.Hudis, C. A.Perou, C. M.Ellis, M. J.Barry, W. T.
- [29] Chemotherapy-induced amenorrhea in premenopausal breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy within the SUCCESS studyJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Neugebauer, Julia KatharinaRack, Brigitte KathrinKupka, MarkusDinkel, CarinaJaeger, Bernadette Anna SophiaOrtmann, UtaSchneeweiss, AndreasSchrader, IrisTesch, HansRezai, MahdiSoeling, UlrikeNoeding, StefanieZabel, FraukeSommer, Harald LeoFriese, KlausBeckmann, Matthias W.Janni, Wolfgang
- [30] Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxaneBreast Cancer, 2011, 18 : 182 - 188Yuko OkanamiYoshinori ItoChie WatanabeKotaro IijimaTakuji IwaseNahomi TokudomeShunji TakahashiKiyohiko Hatake